The independent advisory firm led by former Morgan Stanley investment banking boss Paul Taubman is advising Novartis on a $4bn acquisition — with an ex-head of M&A at the Swiss healthcare company taking the lead.
Novartis will offer $3.9bn in cash to buy Advanced Accelerator Applications, a French company listed in the US that works in molecular nuclear medicine theragnostics, which can be used in diagnosing and treating tumors and some types of cancer.
